Search

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

Supplier Diversity

Poultry

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Results from Phase II MASH trial announced at EASL 2024

Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Medicines reach record number of people, net sales rise

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Clinical Trials

Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.

Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Read more on the Boehringer Ingelheim launched Animal Health vaccine, aimed at protecting poultry from three different diseases.

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Clinical Development and Operations

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

Supplier Diversity

Poultry

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Efficacy and safety of Ofev® (nintedanib) reinforced in new presentations at ATS 2018

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Results from Phase II MASH trial announced at EASL 2024

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

Clinical Trials

Boehringer Ingelheim Announces Jean-Michel Boers as U.S. Country Managing Director, President & CEO Effective August 1, 2020; Dr. Wolfgang Baiker to Retire

Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.

BI Launches Vaccine to Protect Poultry | Boehringer Ingelheim US

Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer